Fresenius Kabi: Adalimumab Customers Want Supply Guarantee, We Can Provide That
Interchangeability ‘More Of A Legal Connotation,’ Firm Tells Generics Bulletin
Following Fresenius Kabi’s approval in mid-December for the eighth and latest biosimilar Humira (adalimumab) product, the company’s senior vice president for biosimilars in the US spoke to Generics Bulletin about how it can stand out from the pack and why it is confident that it can succeed.
